BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $61

Benzinga · 1d ago
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $60 to $61.